Bristol Myers launches new round of major cost cuts
Less than a year after announcing a major cost-cutting campaign, Bristol Myers Squibb is planning another round that will be even larger. On Thursday, the company said it plans to find $2 billion in...
View ArticleLilly posts 45% sales jump, culls four programs across obesity, Alzheimer's,...
Eli Lilly said Thursday that its fourth-quarter revenue jumped 45% to $13.53 billion over the prior year, though this fell short of earlier projections. The drugmaker also reiterated the $58 billion to...
View ArticleAstraZeneca offers some detail on China probe, reaffirms commitment to that...
LONDON — AstraZeneca on Thursday provided insight on an ongoing China probe into the company concerning alleged illegal drug imports, giving investors and analysts some reassurance on the pharma...
View ArticlePersonify Health shares 2024 revenue, profitability
Personify Health, which sells healthcare spending management services to employers, has reached more than half a billion dollars in revenue following the 2023 merger that created the current business....
View ArticlePfizer hires Novartis oncology exec to steer its cancer ambitions
After promoting its oncology officer Chris Boshoff to chief scientific officer last fall, Pfizer has found his successor. Jeff Legos, the global head of oncology at Novartis — which has scored multiple...
View ArticleAffyImmune’s layoffs; Henlius makes a biosimilar deal with Dr. Reddy’s
Plus, news about X4 Pharmaceuticals, Viracta Therapeutics, Crown Laboratories, Qlaris and Hitachi. AffyImmune’s layoffs: The CAR-T biotech went through a round of layoffs and restructuring last month,...
View ArticleJ&J, Intra-Cellular quickly sealed $14B deal as three others passed on buying...
It took one month for Johnson & Johnson to secure its $14 billion acquisition of Intra-Cellular Therapies, according to new securities filings that shed light into the back-and-forth talks behind...
View ArticleAstraZeneca takes $753M charge on abandoned complement drug from Alexion deal
AstraZeneca has terminated all development of vemircopan, the oral factor D inhibitor it acquired through the deal for Alexion in 2021. The UK major recorded an impairment charge of $753 million as a...
View ArticleAstraZeneca cuts UK funding pledge; Viking says it has ‘enough’ API for trials
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. AstraZeneca said it is "very disappointed" in the UK government's...
View ArticleDigital health dealmaking is heating up
We’re in dealmaking season for publicly traded digital health companies. In the last week and a half, Progyny said it’s buying BenefitBump, a parental leave benefits navigation company. Teladoc,...
View ArticleUpdated: Hospital group blasts proposed 340B rebate models, requests to join...
A trade group representing 1,600 hospitals says 340B rebate models proposed by multiple drugmakers would be a “significant burden” to its members, and wants to intervene in the companies' lawsuits...
View ArticleBristol Myers prunes pipeline amid new round of cost cuts
Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials. The pipeline cuts disclosed Thursday follow news of a
View ArticleAcelyrin and Alumis to merge in deal combining cash, assets
After running into clinical hurdles with its “diamond in the rough” strategy, Los Angeles immunology biotech Acelyrin is handing over its last remaining clinical asset and $448 million in cash and...
View ArticleRoche heads to FDA with Gazyva results in a form of lupus
Almost 16 years after Rituxan's disappointing data in lupus, Roche's Genentech found success with a different B cell-killing drug called Gazyva in lupus nephritis — and it’s taking the antibody to the...
View ArticleSionna inks $191M IPO for cystic fibrosis pipeline as Aardvark eyes $89M for...
Cystic fibrosis biotech Sionna Therapeutics will raise $191 million in its upsized Nasdaq debut on Friday, and metabolic disease biotech Aardvark Therapeutics outlined plans for a potential $89 million...
View ArticleLongtime Sandoz exec announces retirement; Lilly appoints head of India
→ Francisco Ballester is retiring as president, region international at Sandoz on March 1, and Peter Stenico will replace him. Ballester has held this role for six years and was president of Latin...
View ArticleNovo Nordisk takes aim at Roche in hemophilia A, but is way behind
Novo Nordisk said Friday that its hemophilia A preventive Mim8 was effective in its pediatric trial, opening it up to a larger patient population after the treatment succeeded in its pivotal ...
View ArticleBain buys Mitsubishi Tanabe Pharma in $3.3B bet on Japan
The Mitsubishi Chemical Group is selling its centuries-old pharmaceutical business to Bain Capital in a carve-out worth about $3.3 billion. The deal comes after Japan’s Ministry of Health, Labour and...
View ArticleBioluminescence Ventures to shut down 15 months after launch
The life science investment firm Bioluminescence Ventures will close its doors less than two years after its founding, despite raising nearly half a billion dollars to put into new companies, Endpoints...
View Article